1. Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009. 361:947–957.
Article
2. Rosell R, Carcereny E, Gervais R, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced
EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012. 13:239–246.
Article
3. Chan SK, Gullick WJ, Hill ME. Mutations of the epidermal growth factor receptor in non-small cell lung cancer: search and destroy. Eur J Cancer. 2006. 42:17–23.
Article
4. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005. 2:e73.
Article
5. Engelman JA, Zejnullahu K, Mitsudomi T, et al.
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science. 2007. 316:1039–1043.
Article
6. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011. 3:75ra26.
Article
7. Jackman D, Pao W, Riely GJ, et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. J Clin Oncol. 2010. 28:357–360.
Article
8. Oxnard GR, Arcila ME, Chmielecki J, Ladanyi M, Miller VA, Pao W. New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res. 2011. 17:5530–5537.
Article
9. Yun CH, Mengwasser KE, Toms AV, et al. The T790M mutation in
EGFR kinase causes drug resistance by increasing the affinity for ATP. Proc Natl Acad Sci U S A. 2008. 105:2070–2075.
Article
10. Doebele RC, Pilling AB, Aisner DL, et al. Mechanisms of resistance to crizotinib in patients with
ALK gene rearranged non-small cell lung cancer. Clin Cancer Res. 2012. 18:1472–1482.
Article
11. Arcila ME, Oxnard GR, Nafa K, et al. Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res. 2011. 17:1169–1180.
Article
12. Oxnard GR, Arcila ME, Sima CS, et al. Acquired resistance to EGFR tyrosine kinase inhibitors in
EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res. 2011. 17:1616–1622.
Article
13. Kwak EL, Sordella R, Bell DW, et al. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A. 2005. 102:7665–7670.
Article
14. Ercan D, Zejnullahu K, Yonesaka K, et al. Amplification of EGFR T790M causes resistance to an irreversible
EGFR inhibitor. Oncogene. 2010. 29:2346–2356.
Article
15. Miller VA, Hirsh V, Cadranel J, et al. Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial. Lancet Oncol. 2012. 13:528–538.
Article
16. Zhou W, Ercan D, Chen L, et al. Novel mutant-selective EGFR kinase inhibitors against
EGFR T790M. Nature. 2009. 462:1070–1074.
Article
17. Banerji U. Heat shock protein 90 as a drug target: some like it hot. Clin Cancer Res. 2009. 15:9–14.
Article
18. Shimamura T, Li D, Ji H, et al. Hsp90 inhibition suppresses mutant
EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res. 2008. 68:5827–5838.
Article
19. Sequist LV, Gettinger S, Senzer NN, et al. Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancer. J Clin Oncol. 2010. 28:4953–4960.
Article
20. Regales L, Gong Y, Shen R, et al. Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest. 2009. 119:3000–3010.
21. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol. 2010. 28:1124–1130.
Article
22. Janjigian YY, Groen HJ, Horn L, et al. Activity and tolerability of afatinib (BIBW 2992) and cetuximab in NSCLC patients with acquired resistance to erlotinib or gefitinib. J Clin Oncol. 2011. 29:Suppl. 7525.
Article
23. Avizienyte E, Ward RA, Garner AP. Comparison of the EGFR resistance mutation profiles generated by EGFR-targeted tyrosine kinase inhibitors and the impact of drug combinations. Biochem J. 2008. 415:197–206.
Article
24. Yano S, Wang W, Li Q, et al. Hepatocyte growth factor induces gefitinib resistance of lung adenocarcinoma with epidermal growth factor receptor-activating mutations. Cancer Res. 2008. 68:9479–9487.
Article
25. Zhang Z, Lee JC, Lin L, et al. Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet. 2012. 44:852–860.
Article
26. Chung JH, Rho JK, Xu X, et al. Clinical and molecular evidences of epithelial to mesenchymal transition in acquired resistance to EGFR-TKIs. Lung Cancer. 2011. 73:176–182.
Article
27. Zakowski MF, Ladanyi M, Kris MG, et al.
EGFR mutations in small-cell lung cancers in patients who have never smoked. N Engl J Med. 2006. 355:213–215.
Article
28. Morinaga R, Okamoto I, Furuta K, et al. Sequential occurrence of non-small cell and small cell lung cancer with the same
EGFR mutation. Lung Cancer. 2007. 58:411–413.
Article
29. Tatematsu A, Shimizu J, Murakami Y, et al. Epidermal growth factor receptor mutations in small cell lung cancer. Clin Cancer Res. 2008. 14:6092–6096.
Article
30. Engelman JA, Mukohara T, Zejnullahu K, et al. Allelic dilution obscures detection of a biologically significant resistance mutation in
EGFR-amplified lung cancer. J Clin Invest. 2006. 116:2695–2706.
Article
31. Ercan D, Xu C, Yanagita M, et al. Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov. 2012. 2:934–947.
Article
32. Takezawa K, Pirazzoli V, Arcila ME, et al.
HER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in
EGFR-mutant lung cancers that lack the secondsite
EGFRT790M mutation. Cancer Discov. 2012. 2:922–933.
Article
33. Blakely CM, Bivoma TG. Resilency of lung cancers to EGFR inhibitor treatment unveiled, offereing opportunities to divide and conquer EGFR inhibitor resistance. Cancer Discov. 2012. 2:872–875.
Article
34. Garofalo M, Romano G, Di Leva G, et al. EGFR and MET receptor tyrosine kinase-altered microRNA expression induces tumorigenesis and gefitinib resistance in lung cancers. Nat Med. 2011. 18:74–82.
Article